Andreas Tiede, Professor, Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, shared a post on LinkedIn:
“This will change Hematology forever: the milder Aza/Ven combination is more effective and less harmful than the traditional 3+7 chemo regimen in fit AML patients.
Groundbreaking data at ASH 2025.”
More posts from ASH 2025.